

Figure 1. UNAIDS compartmental model for estimating mortality in HIV-positive individuals in the absence of ART
 ART=antiretroviral therapy.




Figure 2. HIV relative survival after seroconversion for male and female individuals aged 25–34 years based on the analysis of 13 ART-naïve cohort studies

Solid lines show means; shaded area shows 95% uncertainty intervals (uncertainty intervals not available for UNAIDS data). ART=antiretroviral therapy.




Figure 3. HIV deaths in Thailand (A) and Russia (B) by age in 2005 for both sexes combined
 Data are for vital registration deaths assigned to HIV (red), deaths coded to garbage codes redistributed to HIV (blue), and misclassified deaths reassigned to HIV (green). The height of the bar is the final number of deaths in each age group.




Figure 4. Vital registration inputs, and Spectrum and UNAIDS HIV mortality draws for Panama




Figure 5. Bayesian meta-regression estimates for tuberculosis prevalence (A), incidence (B), remission (C), excess mortality (D), and cause-specific mortality (E) for male individuals in Kenya, 2013

For each observation in black, the length of the horizontal bar refers to the age interval of the observation and the length of the vertical bar refers to the uncertainty interval. To stabilise estimates, all data from 2008 to 2013 are included.




Figure 6. Meta-analysis of published validation studies of verbal autopsy for malaria in adults (A) and children (B), both sexes combined

The solid lines show 95% uncertainty intervals (ui); the dotted lines show the point estimate of the pooled estimate (the diamond). The age cutoff for children is <15 years.




Figure 7. Global HIV incidence (A), prevalence (B), and mortality (C), 1990-2013, for all ages and both sexes combined
Shaded areas are 95% uncertainty intervals.




Figure 8. Global age-sex distribution of new HIV infections (A) and deaths (B) in 2013

Europe PMC Funders Author Manuscripts




Figure 9. Age-standardised HIV incidence (A) and prevalence (B) in 2013, both sexes
 ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.
 FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago.
 TLS=Timor-Leste.




Figure 10. Age-standardised HIV mortality in 2013, both sexes

ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.

FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago.

TLS=Timor-Leste.




Figure 11. Years of life saved (YLS) through prophylactic treatment by region in 1990–2003 (A), 2004–08 (B), and 2009–13 (C), both sexes
 Treatment includes antiretroviral therapy, prevention of mother-to-child transmission, and co-trimoxazole prophylaxis.




Figure 12. Comparison of 43 national HIV prevalence survey results for people aged 15–49 to prevalence estimates from the GBD 2013 and UNAIDS for the same year and age-group Each point corresponds to an estimate for a particular country, survey year, sex, and 5-year age group. The solid line indicates the line of equivalence.




Figure 13. Global tuberculosis incidence (A), prevalence (B), and deaths (C), 1990–2013, for all ages and both sexes combined
 Shaded areas show 95% uncertainty intervals.




Figure 14. Global age-sex distribution of tuberculosis incidence (A) and deaths (B) in HIV-negative individuals in 2013




Figure 15. Age-standardised tuberculosis incidence (A) and death rates (B) in HIV-negative individuals in 2013, both sexes

ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.
 FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago.
 TLS=Timor-Leste.




Figure 16. Global malaria incidence (A) and deaths (B), 1990–2013, for all ages and both sexes combined
Shaded areas are 95% uncertainty intervals.




Figure 17. Global age-sex distribution of malaria incidence (A) and deaths (B) in 2013




Figure 18. Age-standardised malaria incidence (A) and death (B) rates in 2013, both sexes
 ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.
 FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago.
 TLS=Timor-Leste.

Table 1
HIV-specific mortality rates for adults aged 25–34 years on antiretroviral therapy in sub-Saharan Africa, by time since initiation, sex, and initial CD4 count (per 100 person-years)

	Women (time since initiation)			Men (time since initiation)		
	0–6 months	7–12 months	13–24 months	0–6 months	7–12 months	13–24 months
<50 CD4 cells per μL	40.6 (20.4–71.5)	8.9 (6.0–13.4)	4.0 (2.7–5.7)	53.1 (26.5–93.5)	11.6 (7.9–17.5)	5.2 (3.6–7.5)
50–99 CD4 cells per μL	17.4 (12.2–25.0)	6.5 (5.0–8.4)	3.0 (2.3–3.9)	22.8 (16.2–32.4)	8.6 (6.5–11.2)	3.9 (3.0–5.1)
100–199 CD4 cells per μL	14.1 (10.4–18.4)	5.7 (4.4–7.2)	2.6 (2.0–3.3)	18.4 (13.6–24.2)	7.4 (5.8–9.5)	3.4 (2.6–4.3)
200–249 CD4 cells per μL	12.5 (8.9–16.6)	5.1 (3.8–6.5)	2.4 (1.8–3.1)	16.3 (11.6–21.7)	6.6 (4.9–8.6)	3.1 (2.3–4.0)
250–349 CD4 cells per μL	10.7 (7.0–14.8)	4.4 (3.0–6.0)	2.0 (1.4–2.7)	14.0 (9.3–19.4)	5.7 (3.9–7.8)	2.6 (1.8–3.6)
350–499 CD4 cells per μL	8.1 (4.7–12.0)	3.1 (1.8–4.8)	1.4 (0.7–2.2)	10.5 (6.0–15.8)	4.1 (2.4–6.2)	1.8 (1.0–2.8)
≥ 500 CD4 cells per μL	6.3 (0.9–11.0)	2.3 (0.1–4.4)	0.9 (0.0–2.0)	8.2 (1.2–14.7)	3.0 (0.1–5.7)	1.2 (0.0–2.6)

Data in parentheses are 95% uncertainty intervals.

Table 2
Age-standardised HIV/AIDS incidence, prevalence, and mortality rates, and annualised rates of change for both sexes for 21 Global Burden of Disease regions

	Age-standardised rates in 2013 (per 100 000 population)			Annualised rate of change (%)					
	Incidence	Prevalence	Mortality	1990–2000			2000–2013		
				Incidence	Prevalence	Mortality	Incidence	Prevalence	Mortality
Worldwide	24.84 (23.10 to 28.26)	400.98 (385.51 to 435.10)	18.51 (17.38 to 20.46)	1.27 (0.24 to 2.16)	8.87 (8.36 to 9.52)	13.62 (11.93 to 15.38)	-3.92 (-4.50 to -3.15)	-0.20 (-0.42 to 0.05)	-1.54 (-2.36 to -0.59)
High-income Asia Pacific	0.49 (0.28 to 0.70)	7.22 (4.81 to 9.97)	0.10 (0.08 to 0.13)	7.74 (3.65 to 13.26)	6.94 (5.12 to 9.46)	0.77 (-1.11 to 2.92)	-1.55 (-5.91 to 1.57)	6.29 (4.49 to 8.22)	1.13 (-0.55 to 3.20)
Central Asia	7.02 (3.62 to 15.56)	61.98 (38.09 to 105.12)	2.67 (1.52 to 4.08)	8.17 (-3.90 to 19.78)	13.11 (1.09 to 24.09)	21.91 (9.43 to 33.39)	4.18 (-2.22 to 12.58)	5.46 (1.76 to 9.62)	2.65 (-2.01 to 5.83)
East Asia	2.28 (1.31 to 4.09)	26.37 (14.36 to 41.32)	0.77 (0.60 to 1.05)	38.86 (27.75 to 62.64)	41.29 (30.82 to 62.45)	45.26 (29.11 to 70.18)	1.41 (-3.60 to 6.83)	8.07 (4.79 to 11.46)	6.09 (2.91 to 10.38)
South Asia	2.69 (0.85 to 5.51)	93.97 (84.36 to 112.06)	5.42 (4.43 to 7.18)	-9.72 (-15.85 to -5.81)	3.91 (1.89 to 5.98)	13.67 (7.68 to 23.47)	-13.93 (-19.71 to -8.09)	-7.85 (-8.67 to -6.64)	-11.58 (-14.45 to -7.11)
Southeast Asia	13.88 (6.66 to 41.04)	176.39 (113.22 to 421.49)	7.54 (3.90 to 23.55)	-10.46 (-15.54 to -4.52)	8.07 (5.78 to 12.44)	29.51 (25.47 to 33.97)	1.29 (-2.74 to 7.36)	0.97 (-0.78 to 3.51)	-3.87 (-6.62 to 1.36)
Australasia	1.50 (0.81 to 2.32)	35.09 (22.80 to 50.24)	0.37 (0.26 to 0.53)	-7.07 (-11.53 to -3.51)	-1.86 (-3.67 to -0.18)	-11.88 (-14.40 to -9.10)	0.41 (-1.27 to 2.85)	1.07 (-0.53 to 2.49)	-4.51 (-6.49 to -2.60)
Caribbean	32.24 (25.95 to 39.68)	497.47 (450.24 to 551.29)	23.30 (19.26 to 29.15)	-6.32 (-8.01 to -4.81)	1.07 (-0.46 to 3.04)	9.02 (4.68 to 12.88)	-2.93 (-4.21 to -1.46)	-0.83 (-1.46 to -0.25)	-6.04 (-6.91 to -5.03)
Central Europe	0.95 (0.71 to 1.23)	16.62 (13.41 to 20.11)	0.44 (0.37 to 0.51)	1.29 (-1.78 to 4.40)	8.90 (6.61 to 11.36)	8.06 (6.44 to 10.09)	-0.55 (-3.44 to 2.08)	2.37 (1.20 to 3.44)	0.19 (-1.28 to 1.41)
Eastern Europe	22.58 (16.56 to 31.65)	263.86 (209.53 to 347.22)	11.14 (8.75 to 14.14)	25.17 (18.06 to 34.84)	18.47 (14.57 to 24.08)	13.07 (9.88 to 16.41)	-1.53 (-3.75 to 0.86)	4.75 (3.18 to 6.14)	8.51 (6.41 to 10.74)
Western Europe	3.26 (2.56 to 4.22)	80.97 (66.16 to 99.08)	1.06 (0.90 to 1.24)	-9.15 (-14.34 to -5.01)	0.92 (-0.14 to 2.04)	-6.75 (-8.06 to -5.34)	0.05 (-1.77 to 2.05)	0.60 (-0.21 to 1.62)	-3.59 (-4.72 to -2.25)
Andean Latin America	7.96 (4.64 to 16.84)	106.52 (76.06 to 171.80)	3.92 (2.40 to 9.39)	1.91 (-16.44 to 14.95)	11.70 (2.21 to 21.36)	19.73 (11.89 to 28.79)	-1.09 (-6.07 to 4.63)	1.15 (-1.96 to 4.60)	-3.52 (-6.58 to 0.62)
Central Latin America	9.43 (7.48 to 11.55)	139.92 (118.12 to 167.80)	4.08 (3.13 to 6.16)	-2.00 (-8.23 to 1.40)	7.04 (3.66 to 9.32)	13.13 (10.27 to 16.05)	-0.64 (-1.81 to 0.37)	0.99 (-1.33 to 2.31)	-5.46 (-7.10 to -3.86)

Lancet. Author manuscript; available in PMC 2014 October 20.